CoChat

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS: Interactions between C-C chemokine receptor types 2 (CCR2) and 5 (CCR5) and their ligands, including CCL2 and CCL5, mediate fibrogenesis by promoting monocyte/macrophage recruitment and tissue infiltration, as well as hepatic stellate cell activation. Cenicriviroc (CVC) is an oral, dual CCR2/CCR5 antagonist with nanomolar potency against both receptors. CVC's anti-inflammatory and antifibrotic effects were evaluated in a range of preclinical models of inflammation and fibrosis. METHODS: Monocyte/macrophage recruitment was assessed in vivo in a mouse model of thioglycollate-induced peritonitis. CCL2-induced chemotaxis was evaluated ex vivo on mouse monocytes. CVC's antifibrotic effects were evaluated in a thioacetamide-induced rat model of liver fibrosis and mouse models of diet-induced non-alcoholic steatohepatitis (NASH) and renal fibrosis. Study assessments included body and liver/kidney weight, liver function test, liver/kidney morphology and collagen deposition, fibrogenic gene and protein expression, and pharmacokinetic analyses. RESULTS: CVC significantly reduced monocyte/macrophage recruitment in vivo at doses ≥20 mg/kg/day (p < 0.05). At these doses, CVC showed antifibrotic effects, with significant reductions in collagen deposition (p < 0.05), and collagen type 1 protein and mRNA expression across the three animal models of fibrosis. In the NASH model, CVC significantly reduced the non-alcoholic fatty liver disease activity score (p < 0.05 vs. controls). CVC treatment had no notable effect on body or liver/kidney weight. CONCLUSIONS: CVC displayed potent anti-inflammatory and antifibrotic activity in a range of animal fibrosis models, supporting human testing for fibrotic diseases. Further experimental studies are needed to clarify the underlying mechanisms of CVC's antifibrotic effects. A Phase 2b study in adults with NASH and liver fibrosis is fully enrolled (CENTAUR Study 652-2-203; NCT02217475).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0158156

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.
Fig 1 CVC Effect on Monocyte/Macrophage Migration. (A) Monocyte/macrophage recruitment reduced in TG-induced mouse model of peritonitis after pre-treatment with CVC (PO BID or QD dosing); (B) cenicriviroc (1 μM) inhibits CCL2-mediated chemotaxis of activated murine macrophages (F4/80+/CD11b+) ex vivo. *p < 0.05 vs. TG + vehicle control; **p < 0.01 vs. TG + vehicle control; ***p < 0.001 vs. TG + vehicle control; † p < 0.001 vs. TG + DEX; ‡ p = 0.018 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). BID, twice daily; CCL2, C-C chemokine ligand 2; CVC, cenicriviroc; CVC5, CVC 5 mg/kg/day; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; DEX, dexamethasone; PO, oral gavage; QD, once daily; SEM, standard error of the mean; TG, thioglycollate.CC BY · PubMed Central
Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.
Fig 2 Reduction of Plasma ALT Levels in NASH Model. *p < 0.05 vs. vehicle control. aVehicle control: 0.5% [w/v] methylcellulose + 1% Tween®-80 (pH ~1.3). ALT, alanine aminotransferase; BID, twice daily; CVC, cenicriviroc; CVC20, CVC 20 mg/kg/day; CVC100, CVC 100 mg/kg/day; NASH, non-alcoholic steatohepatitis; SD, standard deviation.CC BY · PubMed Central
Fig 3 Reduction in Fibrosis. (A) Representative micrographs of Sirius red-stained liver sections in the rat TAA model (early intervention and established fibrosis; 100x), mouse NASH model (200x) and mouse UUO model (200x). (B) Reduction in collagen deposition in the rat TAA model (early intervention and established fibrosis), mouse NASH modela and mouse UUO modelb. *p < 0.05 vs. sham control; **p < 0.01 vs. vehicle control; ***p < 0.001 vs. vehicle control; †p < 0.05 vs. UUO + vehicle control. aPerivascular area subtracted; bData presented exclude a single outlier from an animal in the CVC20 group, which had a CVF value >2 SDs higher than any other animal in the group. CVF, Collagen Volume Fraction; CVC, cenicriviroc; NASH, non-alcoholic steatohepatitis; SD, standard deviation; SEM, standard error of the mean; TAA, thioacetamide; UUO, unilateral ureteral obstruction.
Fig 3 Reduction in Fibrosis. (A) Representative micrographs of Sirius red-stained liver sections in the rat TAA model (early intervention and established fibrosis; 100x), mouse NASH model (200x) and mouse UUO model (200x). (B) Reduction in collagen deposition in the rat TAA model (early intervention and established fibrosis), mouse NASH modela and mouse UUO modelb. *p < 0.05 vs. sham control; **p < 0.01 vs. vehicle control; ***p < 0.001 vs. vehicle control; †p < 0.05 vs. UUO + vehicle control. aPerivascular area subtracted; bData presented exclude a single outlier from an animal in the CVC20 group, which had a CVF value >2 SDs higher than any other animal in the group. CVF, Collagen Volume Fraction; CVC, cenicriviroc; NASH, non-alcoholic steatohepatitis; SD, standard deviation; SEM, standard error of the mean; TAA, thioacetamide; UUO, unilateral ureteral obstruction.CC BY · PubMed Central
Fig 4 CVC Effects on Extracellular Matrix Protein Content. Mean expression of (A) collagen type I and (B) alpha-SMA in the TAA model compared to vehicle control; mean expression of hydroxyproline content in (C) NASH model and (D) UUO model. alpha-SMA, alpha-smooth muscle actin; BID, twice daily; CVC, cenicriviroc; NASH, non-alcoholic steatohepatitis; QD, once daily; SD, standard deviation; TAA, thioacetamide; UUO, unilateral ureter obstruction.
Fig 4 CVC Effects on Extracellular Matrix Protein Content. Mean expression of (A) collagen type I and (B) alpha-SMA in the TAA model compared to vehicle control; mean expression of hydroxyproline content in (C) NASH model and (D) UUO model. alpha-SMA, alpha-smooth muscle actin; BID, twice daily; CVC, cenicriviroc; NASH, non-alcoholic steatohepatitis; QD, once daily; SD, standard deviation; TAA, thioacetamide; UUO, unilateral ureter obstruction.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Research works printed but not linked: 3

  1. Jalbert E, Byron MM, Shikuma C, Jenkins H, Lefebvre E, Barbour JD. Cenicriviroc achieves high CCR5 receptor occupancy at low nanomolar concentrations. Presented at: 21st Conference on Retroviruses and Opportunistic Infections (CROI 2014); 2014 Mar 3; Boston, MA, USA. 530.
  2. MM Byron, 2015, Dual CCR2/CCR5 antagonism by cenicriviroc efficiently inhibits both MCP-1 and RANTES induced chemokine receptor internalization in murine pro-inflammatory monocytes, J Immunol, 194, 187, 10.4049/jimmunol.194.Supp.187.8 · DOI
  3. M Thompson, 2014, Improvements in APRI and FIB-4 fibrosis scores correlate with decreases in sCD14 in HIV-1 infected adults receiving cenicriviroc over 48 weeks, Hepatology, 60, 424A

Cited by

Items 101–200 of 326

Metadata

Authors
Lefebvre, E., Moyle, G., Reshef, R., Richman, L. P., Thompson, M., Hong, F., Chou, H.-L., Hashiguchi, T., Plato, C., Poulin, D., Richards, T., Yoneyama, H., Jenkins, H., Wolfgang, G., & Friedman, S. L.
Affiliations
  • Chelsea and Westminster Hospital (GB)
  • Columbia University Irving Medical Center (US)
  • University of Pennsylvania (US)
  • AIDS Research Consortium of Atlanta (US)
  • Icahn School of Medicine at Mount Sinai (US)
  • Stelic (Japan) (JP)
  • Charles River Laboratories (Canada) (CA)
Corresponding author
Friedman, Scott L.
Venue
PLOS ONE
Published
2016-06-27
Volume
11
Issue
6
Pages
e0158156
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2467384826
Cited by
323
References
51
Citations by year
2026: 17 · 2025: 20 · 2024: 23 · 2023: 28 · 2022: 33 · 2021: 40 · 2020: 46 · 2019: 30 · 2018: 50 · 2017: 28 · 2016: 8
FWCI
27.92
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
  • Columbia Academic Commons (Columbia University)
Funders
National Institute of General Medical Sciences (T32GM007170)
Topics
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Keywords
cenicriviroc, antifibrotic effect, liver fibrosis, renal fibrosis, nonalcoholic steatohepatitis, monocyte/macrophage recruitment, MCP-1, RANTES, hepatic stellate cell activation, collagen deposition, chemokine signaling, thioacetamide-induced liver fibrosis, diet-induced NASH
MeSH terms
Animals, Chemotaxis, Fibrosis, Imidazoles, Kidney Diseases, Macrophages, Male, Mice, Inbred C57BL, Monocytes, Sulfoxides, Rats, Sprague-Dawley, Mice, Rats, Receptors, CCR2, CCR5 Receptor Antagonists, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.